Pharmaceutical companies are investing heavily in developing weight management solutions due to the global obesity epidemic, resulting in a rise in clinical trials for anti-obesity medications. Recent advancements in drug development are increasingly focusing on long-term sustainability and safety for individuals struggling with weight maintenance. Eli Lilly and Co (LLY) released topline results from the ATTAIN-MAINTAIN Phase 3 trial of orforglipron. This study evaluated orforglipron for weight maintenance over 52 weeks after initial treatment for 72 weeks with the highest tolerated doses of Novo Nordisk A/S's (NVO) Wegovy (semaglutide) or Zepbound (tirzepatide). Participants from SURMOUNT-5 were re-randomized to receive orforglipron or placebo. For more information, the full story is available on Benzinga.com.